R
Ryan J. Sullivan
Researcher at Harvard University
Publications - 450
Citations - 28947
Ryan J. Sullivan is an academic researcher from Harvard University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 60, co-authored 362 publications receiving 19308 citations. Previous affiliations of Ryan J. Sullivan include Brigham and Women's Hospital & Georgetown University.
Papers
More filters
Journal ArticleDOI
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh,Benjamin Izar,Benjamin Izar,Sanjay M. Prakadan,Marc H. Wadsworth,Daniel J. Treacy,John J. Trombetta,Asaf Rotem,Asaf Rotem,Christopher Rodman,Christine G. Lian,George F. Murphy,Mohammad Fallahi-Sichani,Ken Dutton-Regester,Ken Dutton-Regester,Ken Dutton-Regester,Jia-Ren Lin,Ofir Cohen,Parin Shah,Diana Lu,Alex S. Genshaft,Travis K. Hughes,Carly G. K. Ziegler,Samuel W. Kazer,Aleth Gaillard,Kellie E. Kolb,Alexandra-Chloé Villani,Cory M. Johannessen,Aleksandr Andreev,Eliezer M. Van Allen,Eliezer M. Van Allen,Monica M. Bertagnolli,Monica M. Bertagnolli,Peter K. Sorger,Ryan J. Sullivan,Keith T. Flaherty,Dennie T. Frederick,Judit Jané-Valbuena,Charles H. Yoon,Charles H. Yoon,Orit Rozenblatt-Rosen,Alex K. Shalek,Aviv Regev,Aviv Regev,Aviv Regev,Levi A. Garraway +45 more
TL;DR: The cellular ecosystem of tumors is begin to unravel and how single-cell genomics offers insights with implications for both targeted and immune therapies is unraveled.
Journal ArticleDOI
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y. Wang,Joe-Elie Salem,Joe-Elie Salem,Justine V. Cohen,Sunandana Chandra,Christian Menzer,Fei Ye,Shilin Zhao,Satya Das,Kathryn E. Beckermann,Lisa Ha,W. Kimryn Rathmell,Kristin K. Ancell,Justin M. Balko,Caitlin Bowman,Elizabeth J. Davis,David D. Chism,Leora Horn,Georgina V. Long,Matteo S. Carlino,Bénédicte Lebrun-Vignes,Zeynep Eroglu,Jessica C. Hassel,Alexander M. Menzies,Jeffrey A. Sosman,Ryan J. Sullivan,Javid Moslehi,Douglas B. Johnson +27 more
TL;DR: In the largest evaluation of fatal ICI-associated toxic effects published to date to the authors' knowledge, early onset of death with varied causes and frequencies depending on therapeutic regimen is observed.
Journal ArticleDOI
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman,Moshe Sade-Feldman,Keren Yizhak,Stacey L. Bjorgaard,Stacey L. Bjorgaard,John P. Ray,Carl G. de Boer,Russell W. Jenkins,David J. Lieb,Jonathan H. Chen,Jonathan H. Chen,Dennie T. Frederick,Michal Barzily-Rokni,Samuel S. Freeman,Alexandre Reuben,Paul Hoover,Paul Hoover,Alexandra-Chloé Villani,Alexandra-Chloé Villani,Elena Ivanova,Andrew Portell,Patrick H. Lizotte,Amir Reza Aref,Jean Pierre Eliane,Marc R. Hammond,Hans Vitzthum,Shauna M. Blackmon,Bo Li,Bo Li,Vancheswaran Gopalakrishnan,Sangeetha M. Reddy,Zachary A. Cooper,Cloud P. Paweletz,David A. Barbie,Anat Stemmer-Rachamimov,Keith T. Flaherty,Jennifer A. Wargo,Genevieve M. Boland,Ryan J. Sullivan,Gad Getz,Nir Hacohen,Nir Hacohen +41 more
TL;DR: The study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy by targeting novel combinations of factors in exhausted cells.
Journal ArticleDOI
Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor
Yuen W. Shing,Judah Folkman,Ryan J. Sullivan,C Butterfield,James A. H. Murray,Michael Klagsbrun +5 more
TL;DR: A tumor-derived growth factor that stimulates the proliferation of capillary endothelial cells has a very strong affinity for heparin, which makes it possible to purify the growth factor to a single-band preparation in a rapid two-step procedure.
Journal ArticleDOI
EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor,Alice T. Shaw,Lecia V. Sequist,Xiujun Fu,Christopher G. Azzoli,Zofia Piotrowska,Tiffany Huynh,Ling Zhao,Linnea Fulton,Katherine Schultz,Emily Howe,Anna F. Farago,Ryan J. Sullivan,James R. Stone,Subba R. Digumarthy,Teresa Moran,Aaron N. Hata,Yukako Yagi,Beow Y. Yeap,Jeffrey A. Engelman,Mari Mino-Kenudson +20 more
TL;DR: In this paper, the authors evaluated response patterns among EGFR-mutant, ALK-positive, and EGFR wild-type/ALK-negative patients and identified 58 patients treated with PD-1/PD-L1 inhibitors.